Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2015-09, Vol.16 (5), p.e101-e104
Hauptverfasser:	Jenkins, Russell W, Oxnard, Geoffrey R, Elkin, Sheryl, Sullivan, E. Kelly, Carter, Jennifer L, Barbie, David A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma of Lung Aged, 80 and over Antineoplastic Agents - therapeutic use Crizotinib Hematology, Oncology and Palliative Medicine Humans Lung adenocarcinoma Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Male MET Mutation Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-met - genetics Pulmonary/Respiratory Pyrazoles - therapeutic use Pyridines - therapeutic use RNA Splice Sites Splice site mutation Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!